LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.9838 USD -9.74% Market Closed
Market Cap: 25.9m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

LAVA Therapeutics NV
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Total Equity
$51.2m
CAGR 3-Years
89%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Total Equity
$225.8m
CAGR 3-Years
11%
CAGR 5-Years
20%
CAGR 10-Years
30%
ProQR Therapeutics NV
NASDAQ:PRQR
Total Equity
€25m
CAGR 3-Years
-42%
CAGR 5-Years
-16%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Total Equity
$55.8m
CAGR 3-Years
-54%
CAGR 5-Years
-31%
CAGR 10-Years
-1%
argenx SE
XBRU:ARGX
Total Equity
$4.3B
CAGR 3-Years
13%
CAGR 5-Years
45%
CAGR 10-Years
71%
Merus NV
NASDAQ:MRUS
Total Equity
$703.3m
CAGR 3-Years
51%
CAGR 5-Years
56%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
25.9m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.1828 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Total Equity?
Total Equity
51.2m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Total Equity amounts to 51.2m USD.

What is LAVA Therapeutics NV's Total Equity growth rate?
Total Equity CAGR 3Y
89%

Over the last year, the Total Equity growth was -40%. The average annual Total Equity growth rates for LAVA Therapeutics NV have been 89% over the past three years .

Back to Top